Aclaris Therapeutics Inc (ACRS) : Ra Capital Management reduced its stake in Aclaris Therapeutics Inc by 41.12% during the most recent quarter end. The investment management company now holds a total of 1,547,152 shares of Aclaris Therapeutics Inc which is valued at $35,120,350 after selling 1,080,567 shares in Aclaris Therapeutics Inc , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Aclaris Therapeutics Inc makes up approximately 3.59% of Ra Capital Management’s portfolio.
Other Hedge Funds, Including , Fmr reduced its stake in ACRS by selling 130,571 shares or 4.68% in the most recent quarter. The Hedge Fund company now holds 2,659,327 shares of ACRS which is valued at $59,888,044. Aclaris Therapeutics Inc makes up approx 0.01% of Fmr’s portfolio. Tfs Capital sold out all of its stake in ACRS during the most recent quarter. The investment firm sold 33,223 shares of ACRS which is valued $749,179.New York State Common Retirement Fund boosted its stake in ACRS in the latest quarter, The investment management firm added 2,863 additional shares and now holds a total of 14,212 shares of Aclaris Therapeutics Inc which is valued at $299,589. Teacher Retirement System Of Texas sold out all of its stake in ACRS during the most recent quarter. The investment firm sold 1,548 shares of ACRS which is valued $32,322.
Many Wall Street Analysts have commented on Aclaris Therapeutics Inc. Aclaris Therapeutics Inc was Initiated by JMP Securities to “Mkt Outperform” on Sep 30, 2016.
Aclaris Therapeutics Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate A-101 is being developed as an in-office treatment for seborrheic keratosis a non-cancerous skin tumor as well as for other cutaneous indications such as common warts. In addition the Company is engaged in developing a portfolio of Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata and other dermatological conditions. The Company’s products A-201 and A-301 are indicated for the treatment of alopecia areata. The Company’s A-101 product is entering Phase III clinical trials for the treatment of seborrheic keratosis and Phase II clinical trials for the treatment of common warts. The Company’s A-201 and A-301 products are in pre- clinical stage.